Frankfurt - Delayed Quote EUR

Willow Biosciences Inc. (3D7.F)

0.0005

0.0000

(0.00%)

As of 8:00:59 AM GMT+2. Market Open.

WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a biotechnology company focused on industrial manufacturing of ingredients is pleased to announce its financial and operating results for the three months and year ended December 31, 2024, and an update in respect of the disposition of Company's operating subsidiary (as announced via press release on March 14, 2025). Selected financial and operational information is outlined below and should be read with Willow's aud

CNW Group 16 days ago

CANSF
0.00%
WILLOW ANNOUNCES SALE OF OPERATING SUBSIDIARY

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a biotechnology company focused on industrial manufacturing of ingredients, announces that it has entered into a definitive agreement dated March 14, 2025 (the "Agreement") with an privately-held, arms-length entity based in the United Kingdom (the "Purchaser"), pursuant to which the Purchaser will acquire the Company's wholly-owned operating subsidiary, Epimeron USA, Inc. ("Epimeron"), including the Company's biotec

CNW Group 27 days ago

CANSF
0.00%
WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it has initiated a formal strategic review process to identify, assess and evaluate a broad range of potential strategic alternatives.

CNW Group 2 months ago

CANSF
0.00%
WILLOW ANNOUNCES CANCELLATION OF PREVIOUSLY ANNOUNCED NON-BROKERED OFFERING TO PURSUE LESS DILUTIVE ALTERNATIVES

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it will not be proceeding with the non-brokered private placement offering announced by the Company on November 18, 2024, and will instead pursue an alternative financing and non-dilutive transaction to support the capital requirements of Willow.

CNW Group 3 months ago

CANSF
0.00%
WILLOW ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $2.0 MILLION

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces its intention to complete a non-brokered private placement offering (the "Offering") on a best efforts basis for a minimum of 10,000,000 units and a maximum of up to 25,016,762 units of the Company (the "Units") at an issue price of C$0.08 per Unit for minimum gross proceeds

CNW Group 4 months ago

CANSF
0.00%
Willow Biosciences Third Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023)

Willow Biosciences ( TSE:WLLW ) Third Quarter 2024 Results Key Financial Results Revenue: CA$1.70m (up 153% from 3Q...

Simply Wall St. 4 months ago

CANSF
0.00%
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces third quarter financial results and provides a corporate update.

PR Newswire 4 months ago

CANSF
0.00%
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces that it has partnered a high value ingredient from its internal portfolio with a global ingredient manufacturer to fully develop, scale, and commercialize.

CNW Group 4 months ago

CANSF
0.00%
WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced a second program with a leading Active Pharmaceutical Ingredient ("API") manufacturer, to develop a more sustainable, cost-effective manufacturing route for a large volume ingredient used in a therapeutic with a global market in excess of $1 billion. This marks the second development co

PR Newswire 6 months ago

CANSF
0.00%
WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.

Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces signing a commercial license and royalty agreement with Kalsec, Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry. The agreement defines the financial terms for use of Willow's tech

PR Newswire 7 months ago

CANSF
0.00%
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended June 30, 2024, reporting significantly higher revenue and reduced costs.

PR Newswire 7 months ago

CANSF
0.00%
WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it has signed a fully funded strain engineering program (the "Program") with an innovative Ag-Biotech company in the biopesticides sector.

CNW Group 7 months ago

CANSF
0.00%
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on July 26, 2024 (the "Meeting"). A total of 27,685,611 common shares, representing approximately 21.74% of the Company's issued and outstanding shares were represented at the meeting.

CNW Group 8 months ago

CANSF
0.00%
WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce that it has closed its previously announced brokered private placement offering of 16,397,365 units ("Units") of the Company at a price of $0.10 per Unit (the "Issue Price") for aggregate gross proceeds to the Company of $1,639,736.50 (the "Offering").

CNW Group 8 months ago

CANSF
0.00%
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces a corporate update on its operations.

CNW Group 9 months ago

CANSF
0.00%
WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLION

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a brokered private placement offering (the "Offering") of up to 30,000,000 units ("Units") of Willow at an issue price of C$0.10 per Unit (the "Offering Price") to raise aggregate gross proceeds of up to C$3.0 million. Independent Trading Group (ITG) Inc. (the "Agent") has ag

CNW Group 10 months ago

CANSF
0.00%
WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS

Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a multi-product development and licensing partnership with Laurus Labs ("Laurus") (Bombay Stock Exchange Code: 540222; LAURUSLABS-IN: National Stock Exchange of India), a leading research-driven pharmaceutical and biotechnology company with a $3.9 billion market cap that serves global pharmac

PR Newswire 10 months ago

CANSF
0.00%
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further progress in its commercial expansion.

CNW Group 10 months ago

CANSF
0.00%

Performance Overview

Return	3D7.F	S&P/TSX Composite index (^GSPTSE)
YTD	-98.65%	-6.52%
1-Year	-99.12%	+4.09%
3-Year	-99.77%	+5.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Willow Biosciences Inc. (3D7.F)

WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY

WILLOW ANNOUNCES SALE OF OPERATING SUBSIDIARY

WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS

WILLOW ANNOUNCES CANCELLATION OF PREVIOUSLY ANNOUNCED NON-BROKERED OFFERING TO PURSUE LESS DILUTIVE ALTERNATIVES

WILLOW ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $2.0 MILLION

Willow Biosciences Third Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023)

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO

WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS

WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM

WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLION

WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Performance Overview